Technical Analysis for GNFT - GENFIT S.A.

Grade Last Price % Change Price Change
grade F 20.37 -1.02% -0.21
GNFT closed down 1.02 percent on Monday, June 17, 2019, on 43 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical GNFT trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
180 Bearish Setup Bearish Swing Setup -1.02%
Lower Bollinger Band Walk Weakness -1.02%
Below Lower BB Weakness -1.02%

Older signals for GNFT ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
GENFIT is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases. GENFIT concentrates its R&D efforts in areas of high unmet medical needs corresponding to a lack of approved treatments. GENFIT’s lead proprietary compound, elafibranor, is a drug candidate currently being evaluated in one of the most advanced Phase 3 studies worldwide (RESOLVE-IT) in nonalcoholic steatohepatitis, or NASH, considered by regulatory authorities as a medical emergency because it is silent, with potentially severe consequences, and with a prevalence on the rise. Elafibranor has also obtained positive preliminary results in a Phase 2 clinical trial in primary biliary cholangitis, or PBC, a severe chronic liver disease. As part of its comprehensive approach to clinical management of NASH patients, GENFIT is conducting an ambitious discovery and development program aimed at providing patients and physicians with a blood-based test for the diagnosis of NASH, i.e. non-invasive and easy-to-access. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 150 employees.
Medicine Biopharmaceutical Medical Specialties Autoimmune Diseases Hepatitis Hepatology Liver Liver Diseases Diagnostic Solutions Non Alcoholic Fatty Liver Disease Steatohepatitis Liver Disease Obeticholic Acid Primary Biliary Cholangitis
Is GNFT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 26.25
52 Week Low 20.12
Average Volume 99,089
200-Day Moving Average 0.0
50-Day Moving Average 23.945
20-Day Moving Average 23.1405
10-Day Moving Average 22.49
Average True Range 0.857
ADX 24.52
+DI 12.6145
-DI 39.3914
Chandelier Exit (Long, 3 ATRs ) 22.239
Chandelier Exit (Short, 3 ATRs ) 22.691
Upper Bollinger Band 25.8855
Lower Bollinger Band 20.3955
Percent B (%b) 0.0
BandWidth 23.724639
MACD Line -0.7845
MACD Signal Line -0.4064
MACD Histogram -0.3781
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.10
Resistance 3 (R3) 21.11 20.88 20.98
Resistance 2 (R2) 20.88 20.70 20.88 20.94
Resistance 1 (R1) 20.63 20.58 20.51 20.61 20.90
Pivot Point 20.40 20.40 20.34 20.39 20.40
Support 1 (S1) 20.14 20.21 20.03 20.13 19.84
Support 2 (S2) 19.91 20.10 19.91 19.80
Support 3 (S3) 19.66 19.91 19.76
Support 4 (S4) 19.64